Toxic Adenoma epidemiology and demographics

Toxic Adenoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Toxic Adenoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Template:T On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Toxic Adenoma epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Toxic Adenoma epidemiology and demographics
CDC on Toxic Adenoma epidemiology and demographics
Toxic Adenoma epidemiology and demographics in the news
Blogs on Toxic Adenoma epidemiology and demographics
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Toxic Adenoma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]

Epidemiology

Prevalance

• Toxic adenoma prevalence is inversely related to a population’s dietary iodine sufficiency.
• In women and men, the prevalence rate of toxic adenoma is 5-7% and 1-2%, respectively.

Demographics

Age

• The incidence of toxic adenoma increases with age; the median age at diagnosis is 50 years.
• Toxic adenoma is more commonly seen in 56.5% of patients over 60 years but in only 12.5% of the younger patients.

Race

There is no racial predilection to toxic adenoma.

Gender

• Similar to any thyroid disease females are more commonly affected by toxic adenoma than males.
• In women and men, the prevalence rate of palpable nodules is 5-7% and 1-2%, respectively.
• The female-to-male ratio was 14.9:1 for nontoxic AFTNs and 5.9:1 for toxic AFTN patients